<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01635192</url>
  </required_header>
  <id_info>
    <org_study_id>ProGlucose-1</org_study_id>
    <nct_id>NCT01635192</nct_id>
  </id_info>
  <brief_title>Effects of Probiotic VSL#3 on Expression of Small Intestinal Renin-angiotensin System</brief_title>
  <official_title>Effects of Probiotic VSL#3 on Expression of Small Intestinal Mucosal Renin-angiotensin System and Glucose Absorption in Man - a Doubleblind, Randomized Parallel Arm Placebo Controlled Exploratory Study in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Göteborg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Göteborg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Probiotics have become very popular and are by WHO defined as &quot;Live microorganisms which when
      administered in adequate amounts confer a health benefit on the host&quot;. For example,
      probiotics have been shown to contribute to improvements of abdominal discomfort and
      intestinal inflammation. The main hypothesis behind the present study is that probiotics
      influences mucosal regulatory systems, particularly the actions of the hormone Angiotensin II
      locally in the intestinal mucosa.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in mucosal expression of components of renin-angiotensin (particularly ACE1, AT1-receptor, AT2-receptor)</measure>
    <time_frame>Change from baseline in protein expressions after 2 weeks of treatment.</time_frame>
    <description>Mucosal biopsies from jejunum are sampled via endoscopy immediately before (baseline) and at the end of the 2 weeks treatment period. Protein expressions are assessed by western blotting and the subject acts as its own control.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in epithelial permeability and glucose absorption capacity in vitro</measure>
    <time_frame>Change from baseline at 2 weeks after start of treatment.</time_frame>
    <description>Mucosal biopsies are mounted in modified Ussing chambers. Permeability and glucose-absorption are assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in intestinal glucose absorption capacity in-vivo</measure>
    <time_frame>Change from baseline at 2 weeks after start of treatment.</time_frame>
    <description>Glucose (75g) with an non-metabolisable analogue (3-O-methyl-glucose; 2g) is instilled into the duodenum via a nasogastroduodenal tube (corresponding to an oral glucose tolerance test). Plasma glucose, 3OMG and insulin are assessed in 15 min periods over 2h.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>the Local Renin-angiotensin System (RAS) in Small Intestinal Mucosa in Man</condition>
  <arm_group>
    <arm_group_label>VSL#3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Inactive treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VSL#3</intervention_name>
    <description>The probiotic product VSL#3® comes in a powder (sachet) that is to be dissolved in half a glass of cold water before ingestion. Two sachets are ingested once daily over 2 weeks.
Each dose (sachet) contains 450 billion live (lyophilized) lactic acid bacteria (in defined ratios of the following strains: Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus bulgaricus, Streptococcus thermophilus) and are delivered in a base of maltose and silicon dioxide.</description>
    <arm_group_label>VSL#3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Two placebo sachets containing maltose and silicon dioxide are given once daily over 2 weeks.</description>
    <arm_group_label>Inactive treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy volunteers of both sexes

          -  between 18 and 65 years of age.

          -  BMI between 18-25 kg/m2

        Exclusion Criteria:

          -  Any drug abuse

          -  Use of prescription medication within the previous 14 days (with the exception of
             contraceptives)

          -  Pregnant or breast feeding woman or woman of childbearing potential not using adequate
             birth control (e.g. IUD, barrier method, oral contraceptive, abstinence)

          -  In the investigator's judgement, clinically significant abnormalities at the screening
             examination or in the laboratory test results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Fändriks, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Göteborg University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept of Gastrosurgical R&amp;E, Sahlgrenska Universityhospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>SE41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2012</study_first_submitted>
  <study_first_submitted_qc>July 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2012</study_first_posted>
  <last_update_submitted>May 21, 2014</last_update_submitted>
  <last_update_submitted_qc>May 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>renin</keyword>
  <keyword>angiotensin</keyword>
  <keyword>probiotic</keyword>
  <keyword>glucose absorption</keyword>
  <keyword>intestinal</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

